Indication: Chronic Myeloid Leukemia (CML)

AAML1921-ITCC-054: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia

Sub-indication: Chronic Myeloid Leukemia (CML)

Study Type: Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Sponsor: Children's Oncology Group (COG)

Learn more at ClinicalTrials.gov

Email for more information: NCRI-Cancer@NortonHealthcare.org

Search our entire site.